Abstract
Since the 1960s, alkylating agents have been used to treat immune disorders. These agents have also been commonly used in bone marrow transplantation in order to condition the graft recipient, thereby reducing the risk of graft rejection. Cyclophosphamide has been included less frequently in immunosuppressive protocols for other transplant procedures, including renal transplantation. Their most controversial role, however, is in the treatment of autoimmune and chronic inflammatory diseases, particularly those resistant to conventional treatment. This chapter considers the place of alkylating agents in the management of immune disorders. Their contribution to transplantation is described in the appropriate literature. Only chlorambucil and cyclophosphamide are considered in detail because, for practical purposes, these are the only alkylating agents regularly used to treat immune disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahmed, A. R., and Hombal, S., 1987, Use of cyclophosphamide in azathioprine failures in pemphigus, J. Am. Acad. Dermatol. 17:437–442.
Aisenberg, A. C., and Davis, C., 1968, The thymus and recovery from cyclophosphamide induced tolerance to sheep erythrocytes, J. Exp. Med. 128:35–46.
Allemon, A. M., Buc Calderon, P., and Roberfroid, M., 1987, Potentiation of the therapeutic activity of cyclophosphamide by an original N-acyldehydroalanine, Drugs. Exp. Clin. Res. 13:359–365.
Ambrus, J. L., and Fauci, A. S., 1984, Diffuse histiocytic lymphoma in a patient treated with cyclophosphamide for Wegener’s granulomatosis, Am. J. Med. 76:745–747.
American Rheumatism Association, 1970, A controlled trial of cyclophosphamide in rheumatoid arthritis, N. Engl. J. Med. 283:883–889.
Ammenheuser, M. M., Ward, J. B., Jr., Whorton, E. B., Jr., Killian, J. M., and Legator, M. S., 1988, Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: A prospective study, Mutat. Res. 204:509–520.
Amor, B., and Mery, C., 1983, Chlorambucil in rheumatoid arthritis, in: Anti-rheumatic Drugs (I. Huskisson, ed.), Praeger, New York, pp. 605–622.
Arndt, C. A. S., Balis, F. M., McCully, C. L., Colvin, O. M., and Poplack, D. G., 1988, Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys, Cancer Res. 48:2113–2115.
Austin, H. A., III, Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D, Plotz, P. H., and Decker, J. L., 1986, Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs, N. Engl. J. Med. 314:614–619.
Backer, L. C., Gibson, J. B., Moses, M. J., and Allen, J. W., 1988, Synaptonemal complex damage in relation to meiotic chromosome aberrations after exposure of male mice to cyclophosphamide, Mutat. Res. 203:317–330.
Baker, G. L., Kahl, L. E., Zee, B. C., Stolzer, B. L., Agarwal, A. K., and Medsger, T. A., Jr., 1987, Malignancy following treatment of rheumatoid arthritis with cyclophosphamide, Am. J. Med. 83:1–9.
Baltus, J. A. M., Boersma, J. W., Hartman, A. P., and Vandenbroucke, J. P., 1983, The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up, Ann. Rheum. Dis. 42:368–373.
Bank, B. B., Kanganis, D, Liebes, L. E., and Silber, R., 1989, Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes, Cancer Res. 49:554–559.
Benson, A. J., Martin, C. N., and Gardner, R. C., 1988, N-(2-nydroxytheyl)-N-[2-(7-guaninyl)ethyl]amine, the putative major DNA adduct of cyclophosphamide in vitro and in vivo in the rat, Biochem. Pharmacol. 37:2979–2985.
Berd, D., and Mastrangelo, M. J., 1987, Elimination of immune suppressor mechanisms in humans by oxazaphosphorines, Methods Find. Exp. Clin. Pharmacol 9:569–577.
Berd, D., and Mastrangelo, M. J., 1988, Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor-inducer T-cells, Cancer Res. 48:1671–1675.
Berglund, K., Keller, C., and Thysell, H., 1987, Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease, Ann. Rheum. Dis. 46:757–762.
Binder, A. I., So, A., Ansell, B. M., and Denman, A. M., 1986, Intensive immunosuppression in intractable rheumatoid arthritis, Br. J. Rheumatol. 25:380–383.
Boumpas, D. T., Barez, S., Klippel, J. H., and Balow, J. E., 1990, Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus, Ann. Intern. Med. 112:674–677.
Bradley, J. D., Brandt, K. D., and Katz, B. P., 1989, Infectious complications of cyclophosphamide treatment for vasculitis, Arthritis Rheum. 32:45–53.
Brahm, M., Balslov, J. T., Brammer, M., Brun, C., Gerstoft, J., Jorgensen, H. E., Kamper, A., Larsen, S., Lorenzen, I., and Thomsen, A. C., 1988, Cytostatic treatment of glomerular diseases. V. Treatment of glomerulonephritis with cyclo-phosphamide plus prednisone, azathioprine plus prednisone and cyclophosphamide as monotherapy. A comparative study. A report from a Copenhagen study group of renal diseases, Acta Med. Scand. 224:605–610.
Brinkman, C. J. J., Nillesen, W. M., and Hommes, O. R., 1984, The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis, Acta Neurol. Scand. 69:90–96.
Brock, N., 1989, Oxazaphosphorine cytostatics: Past-present-future. Seventh Cain Memorial Award Lecture, Cancer Res. 49:1–7.
Bryant, M. E., Erexson, G. L., and Kligerman, A. D., 1989, A comparison of sister-chromatid exchange in mouse peripheral blood lymphocytes exposed in vitro and in vivo to phosphoramide mustard and 4-hydroxycyclophosphamide, Mutat. Res. 222: 271–277.
Budel, V, Kiss, R., de Launoit, Y., Danguy, A., Atassi, G., Pasteels, J. L., and Paridaens, R., 1988, Prevention of ovarian damage induced by cyclophosphamide in adult female mice by hormonal manipulations, J. Reprod. Fert. 84:625–633.
Calabresi, P., and Parks, R. E., 1980, Antiproliferative agents and drugs used for immunosuppression, in: The Pharmacological Basis of Therapeutics, Vlth ed. (A. G. Gilman et al, eds.), Macmillan, New York, p. 1256.
Cannon, G. W., Jackson, C. G., Samuelson, C. O., Jr., Ward, J. R., Williams, H. J., and Clegg, D. O., 1985, Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review, Semin. Arthritis Rheum. 15:106–118.
Carter, J. L., Dawson, D. M., Hafler, D. A., Fallis, R. J., Stazzone, L., Orav, J., and Weiner, H. L., 1988a, Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis, Ann. NY Acad. Sci. 540:535–536.
Carter, J. L., Hafler, D. A., Dawson, D. M., Orav, J., and Weiner, H. L., 1988b, Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: Cumulative 6-year experience in 164 patients, Neurology 38:9–14.
Ciobanu, N., Runowicz, C., Gucalp, R., Frank, M., Charuvanki, V, Kaufman, D., and Wiernik, P. H., 1987, Reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for ovariancarcinoma, Cancer Treat. Rep. 71:1324–1325.
Clements, P. J., and Levy, J., 1977, Relative cell sizes of lymphocyte populations: The effect of immunosuppressive therapy, Clin. Immunol Immunopathol. 7:69–76.
Cohen-Tervaert, J. W., Hultema, M. G., Hene, R. J., Sluiter, W J., The, T H., van der Hem, G. K., and Kallenberg, C. G., 1990, Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre, Lancet 336:709–711.
Colburn, K. K., Cao, J. D, Krick, E. H., Mortensen, S. E., and Wong, L. G., 1985, Hodgkin’s lymphoma in a patient treated for Wegener’s granulomatosis with cyclophosphamide and azathioprine, J. Rheumatol. 12:599–602.
Csuka, M. E., Carrera, G. F., and McCarty, J., 1986, Treatment of intractable rheumatoid arthritis with combined cyclo-phosphamide, azathioprine, and hydroxychloroquine: A follow-up study, J. Am. Med. Assoc. 255:2315–2319.
Currey, H. L. E., Harris, J., Mason, R. M., Woodland, J., Beveridge, T., Roberts, C. J., Vere, D. W., Dixon, A. St. J., Davies, J., and Owen-Smith, B., 1974, Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis, Br. Med. J. 3:763–766.
Darroudi, E., Targa, H., and Natarajan, A. T., 1988, Influence of dietary carrot on cytostatic drug activity of cyclophosphamide and its main directly acting metabolite: Induction of sister-chromatid exchanges in normal human lymphocytes, Chinese hamster ovary cells, and their DNA repair-deficient call lines, Mutat. Res. 198:327–335.
Denman, A. M., 1982, Immunosuppression and the rheumatic diseases, Ann. Rheum. Dis. 41:S3–8.
Denman, E. J., Denman, A. M., Greenwood, B. M., Gall, D, and Heath, R. B., 1970, Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis, Ann. Rheum. Dis. 29:220–231.
Doll, D C., and Weiss, R. B., 1985, Hemolytic anemia associated with antineoplastic agents, Cancer Treat. Rep. 69:777–782.
Ehling, U. H., and Neuhauser-Klaus, A., 1988, Induction of specific-locus and dominant-le thai mutations by cyclophosphamide and combined cyclophosphamide-radiation treatment in male mice, Mutat. Res. 199:21–30.
Eidinoff, H., 1988, Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid, Med. Hypotheses 26: 103–106.
Erban, S. R., and Sokas, R. K., 1988, Kaposi’s sarcoma in an elderly man with Wegener’s granulomatosis treated with cyclophosphamide and corticosteroids, Arch. Intern. Med. 148:1201–1203.
Erlichman, C., Soldin, S. J., Hardy, R. W., Thiessen, J. J., Sturgeon, J. F. G., Fine, S., and Baskerville, T., 1988, Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma, Arzneimittelforsch. 38:839–842.
Euler, H. H., Gutschmidt, H. J., Schmuecking, M., Schroeder, J. O., and Loffler, H., 1990, Induction of remission in severe SLE after plasma exchange synchronized with subsequent pulse cyclophosphamide, Prog. Clin. Biol. Res. 337:319–320.
Fauci, A. S., Katz, P., Haynes, B. E., and Wolff, S. M., 1979, Cyclophosphamide therapy of severe systemic necrotizing vasculitis, N. Engl. J. Med. 301:235–238.
Fauci, A. S., Haynes, B. E., Katz, P., and Wolff, S. M., 1983, Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years, Ann. Intern. Med. 98:76–85.
Feehally, J., Beattie, T. J., Brenchley, P. E., Coupes, B. M., Houston, I. B., Mallick, N. P., and Postelthwaite, R. J., 1984, Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy, N. Engl. J. Med. 310:415–420.
Firkin, F. C., and Maher, D., 1988, Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia, Eur. J. Haematol 41:212–217.
Ford, C. D., and Wamick, C. T., 1988, DNA damage and repair in patients receiving high-dose cyclophosphamide and radiation, NCI Monogr. 6:41–44.
Fort, J. G., and Abruzzo, J. L., 1988, Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone, Arthritis Rheum. 31:1194–1198.
Furst, D. E., Clements, P. J., Hillis, S., Lachenbruch, P. A., Miller, B. L., Sterz, M. G., and Paulus, H. E., 1989, Immunosuppression with chlorambucil, versus placebo, for scleroderma, Arthritis Rheum. 32:584–593.
Giles, F. J., Smith, M. P., and Goldstone, A. H., 1990, Chlorambucil lung toxicity, Acta Haematol. Basel 83:156–158.
Girard, D., Aloisi, R. M., Bliven, M. L., Cunningham, A. C., and Otterness, I. G., 1990, Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice, Agents Actions 29:333–341.
Goodpasture, J. C., Bergstrom, K., and Vickery, B. H., 1988, Potentiation of the gonadotoxicity of cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist, Cancer Res. 48:2174–2178.
Gudbjornsson, B., and Hallgren, R., 1990, Cutaneous polyarteritis nodosa associated with Crohn’s disease. Report and review of the literature, J. Rheumatol 17:386–390.
Hadidi, A. H., Coulter, C. E., and Idle, J. R., 1988, Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients, Cancer Res. 48:5167–5171.
Hilgard, P., 1987, The metabolism of oxazaphosphorines—An introduction, Methods Find. Exp. Clin. Pharmacol. 9:551–553.
Hitchins, R. N., Hocker, G. A., and Thomson, D. B., 1987, Chlorambucil allergy—A series of three cases, Aust. NZ J. Med. 17:600–602.
Hollingworth, P., de Vere Tyndall, A., Ansell, B. M., Platts-Mills, T., Gumpel, J. M., Mertin, J., Smith, D. S., and Denman, A. M., 1982, Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases, Ann. Rheum. Dis. 41:557–562.
Honjo, I., Suou, T., and Hirayama, C., 1988, Hepatotoxicity of cyclophosphamide in man: Pharmacokinetic analysis, Res. Comm. Chem. Pathol. Pharmacol. 61:149–165.
Hosokawa, M., Sawamura, Y., Morikage, T., Okada, F., Xu, Z. Y., Morikawa, K., Itoh, K., and Kobayashi, H., 1988, Improved therapeutic effects of interleukin-2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide, Cancer Immunol. Immunother. 26:250–256.
Jonsson, R., Tarkowski, A., and Backman, K., 1988, Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice, Agents Actions 25;368–374.
Killian, J. M., Bressler, R. B., Armstrong, R. M., and Huston, D. P., 1988, Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis, Arch. Neurol. 45:27–30.
Kinlen, L. J., 1982, Immunosuppressive therapy and cancer, Cancer Surv. 1:565–583.
Kinlen, L. J., 1985, Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment, Am. J. Med. 78:44–49.
Kirshon, B., Wasserstrum, N., Willis, R., Herman, G. E., and McCabe, E. R. B., 1988, Teratogenic effects of first-trimester cyclophosphamide therapy, Obstet. Gynecol. 72:462–464.
Klein, H. O., Kreysch, H. G., Coerper, C., Voigt, P., and Ruff, I., 1987, Preclinical and early clinical trial with mafosfamide as immune modulator, Methods Find. Exp. Clin. Pharmacol. 9:627–640.
Kodama, M., and Kodama, T., 1988, Effect of a rice-rich diet on the therapeutic efficacy of cyclophosphamide with special reference to the enhancement of transplantation immunity, Jpn J. Cancer Res. 79:608–617.
Kolitz, J. E., Wong, G. Y., Weite, K., Merluzzi, V. J., Egbert, A., Bialas, T., Polivka, A., Bradley, E. C., Konrad, M., Gnecco, C., Oettgen, H. F., and Mertelsmann, R., 1988, Phase I trial of recombinant interleukin-2 and cyclophosphamide: Augmentation of cellular immunity and T cell mitogenic response with long-term administration of rIL-2, J. Biol. Response Mod. 7:457–472.
Kovarsky, J., 1983, Clinical pharmacology and toxicology of cyclophosphamide: Emphasis on use in rheumatic diseases, Sem. Arthritis Rheum. 12:359–372.
Kritharides, L., Lawrie, K., and Varigos, G. A., 1987, Cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil, Cancer Treat. Rep. 71:1323–1324.
Kroneman, O. C., III, and Pevzner, M., 1986, Failure of cyclophosphamide to prevent cerebritis in Wegener’s granulomatosis, Am. J. Med. 80:526–527.
Lahdetie, J., 1988, Induction and survival of micronuclei in rat spermatids. Comparison of two meiotic micronucleus techniques using cyclophosphamide, Mutat. Res. 203:47–53.
Laing, T. J., 1988, Gastrointestinal vasculitis and pneumatosis intestinalis due to systemic lupus erythematosus: Successful treatment with pulse intravenous cyclophosphamide, Am. J. Med. 85:555–558.
Lamers, K., Uitdehaag, B. M. J., Hommes, O. R., Doesberg, W., Wevers, R., van Geel, W. J. A., 1988, The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis, J. Neurol. Neurosurg. Psychiatry 51:1334–1337.
Lauta, V. M., Valerio, G., Greco, A., and Minutolo, M. C., 1987, Early-onset diagnosis of lung toxicity caused by cyclo-phosphamide, melphalan and procarbazine therapy, Tumori 73:351–358.
Lawley, P. D., Topper, R., Denman, A. M., Hylton, W., Hill, I. D, and Harris, G., 1988, Increased sensitivity of lymphocytes from patients with systemic autoimmune diseases to DNA alkylation by the methylating carcinogen N-methyl-N-nitrosourea, Ann. Rheum. Dis. 47:445–451.
Likosky, W. H., 1988, Experience with cyclophosphamide in multiple sclerosis—The cons, Neurology 38:14–18.
Mason, D. H., Jr., and Furst, D. E., 1989, Methotrexate in rheumatoid arthritis and related diseases, Curr. Opinion Rheumatol 1:44–51.
Mathieson, P. W., Turner, A. N., Maidment, C. G. H., Evans, D. J., and Rees, A. J., 1988, Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function, Lancet 2:869–872.
McBride, W. H., Hoon, D. B, Jung, T., Naungayan, J., Nizze, A., and Morton, D. L., 1987, Cyclophosphamide-induced alterations in human monocyte functions, J. Leukocyte Biol. 42:659–666.
McCune, W. J., Golbus, J., Zeldes, W., Böhlke, P., Dunne, R., and Fox, D. A., 1988, Clinical and immunologie effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus, N. Engl. J. Med. 318:1423–1431.
Mertin, J., Rudge, P., Kremer, M., Healey, M. J. R., Knight, S. C., Compston, A., Batchelor, J. R., Thompson, E. J., Halliday, A. M., Denman, A. M., and Medawar, P. B., 1982, Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: Final report, Lancet 2:351–354.
Moore, M. J., Hardy, R. W., Thiessen, J. J., Soldin, S. J., and Erlichman, C., 1988, Rapid development of enhanced clearance after high-dose cyclophosphamide, Clin. Pharmacol. Ther. 44:622–628.
Mountz, J. D, Mushinski, J. E., Smith, H. R., Kilnman, D. M., and Steinberg, A. D., 1985, Modulation of c-myb transcription in autoimmune disease by cyclophosphamide, J. Immunol. 135:2417–2422.
Nikcevich, D. A., Duffie, G. P., Young, M. R., Ellis, N. K., Kaufman, G. E., and Wepsic, H. T., 1987, Simulation of suppressor cells in the bone marrow and spleens of high-dose cyclophosphamide-treated C57B1/6 mice, Cell Immunol. 109:349–359.
Nilsson, I. M., Berntorp, E., and Zettervali, O., 1988, Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII, N. Engl. J. Med. 318:947–950.
O’Duffy, J. D, Robertson, D. M., and Goldstein, N. P., 1984, Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet’s disease, Am. J. Med. 76:75–84.
Ohyashiki, K., Kocova, M., Ryan, D. H., Rowe, J. M., and Sandberg, A. A., 1986, Secondary acute myeloblastic leukemia with a Ph translocation in a treated Wegener’s granulomatosis, Cancer Genet. Cytogenet. 19:331–333.
Padmanabhan, R., 1988, Light microscopic studies on the pathogenesis of exencephaly and cranioschisis induced in the rat after neural tube closure, Teratology 37:29–36.
Palmer, R. G., and Denman, A. M., 1984, Malignancies induced by chlorambucil, Cancer Treat. Rev. 11:121–129.
Palmer, R. G., Dore, C. J., and Denman, A. M., 1984, Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative, Lancet 1:246–249.
Palmer, R. G., Varonos, S., Dore, C. J., Denman, A. M., and Ansell, B. M., 1985, Chlorambucil induced chromosome damage in juvenile chronic arthritis, Arch. Dis. Child. 60:1008–1013.
Palmer, R. G., Dore, C. J., and Denman, A. M., 1986, Cyclophosphamide induces more chromosome damage than chlorambucil in patients with connective tissue diseases, Q. J. Med. 228:395–400.
Palmer, R. G., Smith-Burchnell, C. A., Dore, C. J., and Denman, A. M., 1987, Sensitivity of lymphocytes from patients with systemic lupus erythematosus to the induction of sister chromatid exchanges by alkylating agents and bromodeoxyuridine, Ann. Rheum. Dis. 46:110–113.
Palmer, R. G., Smith-Burchnell, C. A., Pelton, B. K., Hylton, W., and Denman, A. M., 1988, Use of T cell cloning to detect in vivo mutations induced by cyclophosphamide, Arthritis Rheum. 31:757–761.
Pasricha, J. S., Thanzama, J., and Khan, U. K., 1988, Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus, Br. J.J. Dermatol. 119:73–77.
Patapanian, H., Graham, S., Sambrook, P. N., Browne, C. D, Champion, G. D, Cohen, M. L., and Day, R. O., 1988, The oncogenicity of chlorambucil in rheumatoid arthritis, Br. J.J. Rheumatol. 27:44–47.
Paulus, H. E., 1990, The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis, Arthritis Rheum. 33:113–120.
Pedersen-Bjergaard, J., Ersboll, J., Hansen, V. L., Sorensen, B. L., Christoffersen, K., Hou-Jensen, K., Nissen, N. I., Knudsen, J. B., and Hansen, M. M., 1988, Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma, N. Engl. J. Med. 318:1028–1032.
Pestronk, A., Cornblath, D. R., Ilyas, A. A., Baba, H., Quarles, R. H., Griffin, J. W., Anderson, K., and Adams, R. N., 1988, A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside, Ann. Neurol 24:73–78.
Pitt, P. I., Sultan, A. H., Malone, M., Andrews, V, and Hamilton, E. B. D, 1987, Association between azathioprine therapy and lymphoma in rheumatoid disease, J. R. Soc. Med. 80:428–429.
Pohl, J., Reissmann, T., and Voegeli, R., 1987, Oxazaphosphorine effects in L 5222 rat leukemia, Methods Find. Exp. Clin. Pharmacol 9:589–594.
Ponticelli, C., Zucchelli, P., Passerini, P., Cagnoli, L., Cesana, B., Pozzi, C., Pasquali, S., Imbasciati, E., Grassi, C., Redaelli, B., Sasdelli, M., and Locatelli, F., 1989, A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy, N. Engl. J. Med. 320:8–13.
Pool, B. L., Bos, R. P., Niemeyer, U., Theuws, J. L. G., and Schmahl, D. 1988, In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide—A study aimed at clarifying the mechanism of Mesna’s anticarcinogenic activity, Toxicol Lett. 41:49–56.
Powis, G., Reece, P., Ahmann, D. L., and Ingle, J. N., 1987, Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients, Cancer Chemother. Pharmacol. 20:219–222.
Rees, A. J., and Lockwood, C. M., 1982, Immunosuppressive drugs in clinical practice, in: Clinical Aspects of Immunology, IVth ed. (P. J. Lachmann and D. K. Peters, eds.), Blackwells, Oxford, pp. 507–564.
Sargent, L. M., Roloff, B., and Meisner, L. F., 1987, Mechanisms in cyclophosphamide induction of cytogenetic damage in human lymphocyte cultures, Cancer Genet. Cytogenet. 29:239–243.
Scheper, R. J., Limpens, J., Tan, B. T. G., Valster, H., Claessen, A. M. E., and Claessen, M. E., 1987, Immunotherapeutic effects of local chemotherapy with an active metabolite of cyclophosphamide, Methods Find. Exp. Clin. Pharmacol. 9:611–615.
Schilsky, R. L., Lewis, B. J., Sherins, R. J., and Young, R. C., 1980, Gonadal dysfunction in patients receiving chemotherapy for cancer, Ann. Intern. Med. 93:109–114.
Schüler, U., Ehninger, G., and Wagner, T., 1987, Repeated high-dose cyclophosphamide administration in bone marrow transplantation: Exposure to activated metabolites, Cancer Chemother. Pharmacol 20:248–252.
Scott, D. G. I., and Bacon, P. A., 1984, Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis, Am. J. Med. 76:377–384.
Scott, D. G. I., Bacon, P. A., Elliott, P. J., Tribe, C. R., and Wallington, T. B., 1982, Systemic vasculitis in a district general hospital 1972-1980: Clinical and laboratory features, classification and prognosis of 80 cases, Q. J. Med. 51:292–311.
Sessoms, S. L., and Kovarsky, J., 1984, Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus, Clin. Exp. Rheumatol. 2:247–251.
Sewell, W. A., de Moerloose, P. A., Hamilton, J. A., Schrader, J. W., Mackay, I. R., and Vadas, M. A., 1987, Potentiation of delayed-type hypersensitivity by pertussigen or cyclophosphamide with release of different lymphokines, Immunobgy 61; 483–488.
Shaunak, S., Munro, J. M., Weinbren, K., Walport, M. J., and Cox, T. M., 1988, Cyclophosphamide-induced liver necrosis: A possible interaction with azathioprine, Q. J. Med. 67:309–317.
Shaw, I. C., 1987, Mesna and oxazaphosphorine cancer chemotherapy, Cancer Treat. Rev. 14:359–364.
Shen, R. N., Hornback, N. B., Shidnia, H., Lu, L., Broxmeyer, H. E., and Brahmi, Z., 1988, Effect of whole-body hyperthermia and cyclophosphamide on natural killer cell activity in murine erythroleukemia, Cancer Res. 48:4561–4563.
Shiraki, M., Fujiwara, M., and Tomura, S., 1984, Long-term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis, Clin. Exp. Immunol. 55:333–339.
Silman, A. J., Petrie, J., Hazleman, B., and Evans, S. J. W., 1988, Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow-up study, Ann. Rheum. Dis. 47:988–992.
Simel, D. L., St. Clair, E. W., Adams, J., and Greenberg, C. S., 1987, Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome, Am. J. Med. 83:563–566.
Slott, V. L., and Hales, B. E., 1988, Role of the 4-hydroxy intermediate in the in vitro embryotoxicity of cyclophosphamide and dechlorocyclophosphamide, Toxicol Appl. Pharmacol. 92:170–178.
Smith, J. J., Mihich, E., and Ozer, H., 1987, In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function, Methods Find. Exp. Clin. Pharmacol. 9:555–568.
Smyth, M. J., Pietersz, G. A., and McKenzie, I. F. C., 1987, The Cellular uptake and cytotoxicity of chlorambucil-monoclonal antibody conjugates, Immunol. Cell. Biol 65:315–321.
Sorsa, M., Pyy, L., Salomaa, S., Nylund, L., and Yager, J. W., 1988, Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals, Mutat. Res. 204:465–479.
Stevenson, H. C., and Fauci, A. S., 1980, Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B cell activation, Immunology 39:391–397.
Stillwell, T. J., and Benson, R. C., 1988, Cyclophosphamide-induced hemorrhagic cystitis, Cancer 61:451–457.
Strange, C., Halstead, L., Baumann, M., and Sahn, S. A., 1990, Subglottic stenosis in Wegener’s granulomatosis: Development during cyclophosphamide treatment with response to carbon dioxide laser therapy, Thorax 45:300–301.
Swanson, M. A., and Schwartz, R. S., 1967, Immunosuppressive therapy: The relation between clinical response and immunologic competence, N. Engl. J. Med. 277:163–170.
Sy, M. S., and Miller, S. D., and Claman, H. N., 1977, Immune suppression with supraoptimal doses of antigen in contact sensitivity, J. Immunol. 119:240–244.
Tessler, H. H., and Jennings, T., 1990, High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet’s disease, Br. J.J. Ophthalmol. 74:353–357.
Thatte, U. M., Chhabria, S. N., Karandikar, S. M., and Dahanukar, S. A., 1987, Protective effects of Indian medical plants against cyclophosphamide neutropenia, J. Postgrad. Med. 33:185–188.
Thomas, M. R., Robinson, W. A., Boyle, D. J., Day, J. E., Entringer, M. A., and Steigerwald, J. E., 1983, Long-term effects of cyclophosphamide on granulocyte colony formation in patients with rheumatoid arthritis, J. Rheumatol. 10:778–783.
Thompson, C. A., 1990, Safe handling of cyclophosphamide, Am. J. Hosp. Pharm. 47:75–76.
Thrasher, J. B., Miller, G. J., and Wettlaufer, J. N., 1990, Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis, J. Urol 143:119–121.
Tietjen, D. P., and Moore, W. J., 1990, Treatment of rapidly progressive glomerulonephritis due to Behçet’s syndrome with intravenous cyclophosphamide, Nephron 55:69–73.
Turk, J. L., 1987, Enhancement of the delayed-type hypersensitivity reaction by oxazaphosphorines, Methods Find. Exp. Clin. Pharmacol. 9:605–610.
Vandenberg, S. A., Kulig, K., Spoerke, D. G., Hall, A. H., Bailie, V. J., and Rumack, B. H., 1988, Chlorambucil overdose: Accidental ingestion of an antineoplastic drug, J. Emerg. Med. 6:495–498.
Wessel, G., Abendroth, K., and Wisheit, M., 1988, Malignant transformation during immunosuppressive therapy (azathioprine) of rheumatoid arthritis and systemic lupus erythematosus. A retrospective study, Scand. J. Rheum. 67:73–75.
Williams, H. J., Reading, J. C., Ward, J. R., and O’Brien, W. M., 1980, Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis, Arthritis Rheum. 23:521–527.
Workman, P., Oppitz, M., Donaldson, J., and Lee, F. Y. E., 1987, High-performance liquid chromatography of chlorambucil analogues, J. Chromatogr. 422:315–321.
Yager, J. W., Sorsa, M., and Selvin, S., 1988, Micronuclei in cytokinesis-blocked lymphocytes as an index of occupational exposure to alkylating cytostatic drugs, IARC Sci. Publ. 89:213–216.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Denman, A.M., Denman, D.J., Palmer, R.G. (1992). Alkylating Agents. In: Rugstad, H.E., Endresen, L., Førre, Ø. (eds) Immunopharmacology in Autoimmune Diseases and Transplantation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1167-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1167-4_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1169-8
Online ISBN: 978-1-4899-1167-4
eBook Packages: Springer Book Archive